Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Plasma P-tau181 in Alzheimer’s disease : relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia

Janelidze, Shorena LU ; Mattsson, Niklas LU orcid ; Palmqvist, Sebastian LU orcid ; Smith, Ruben LU ; Beach, Thomas G. ; Serrano, Geidy E. ; Chai, Xiyun ; Proctor, Nicholas K. ; Eichenlaub, Udo and Zetterberg, Henrik LU , et al. (2020) In Nature Medicine 26(3). p.379-386
Abstract

Plasma phosphorylated tau181 (P-tau181) might be increased in Alzheimer’s disease (AD), but its usefulness for differential diagnosis and prognosis is unclear. We studied plasma P-tau181 in three cohorts, with a total of 589 individuals, including cognitively unimpaired participants and patients with mild cognitive impairment (MCI), AD dementia and non-AD neurodegenerative diseases. Plasma P-tau181 was increased in preclinical AD and further increased at the MCI and dementia stages. It correlated with CSF P-tau181 and predicted positive Tau positron emission tomography (PET) scans (area under the curve (AUC) = 0.87–0.91 for different brain regions). Plasma P-tau181 differentiated AD dementia from non-AD neurodegenerative diseases with... (More)

Plasma phosphorylated tau181 (P-tau181) might be increased in Alzheimer’s disease (AD), but its usefulness for differential diagnosis and prognosis is unclear. We studied plasma P-tau181 in three cohorts, with a total of 589 individuals, including cognitively unimpaired participants and patients with mild cognitive impairment (MCI), AD dementia and non-AD neurodegenerative diseases. Plasma P-tau181 was increased in preclinical AD and further increased at the MCI and dementia stages. It correlated with CSF P-tau181 and predicted positive Tau positron emission tomography (PET) scans (area under the curve (AUC) = 0.87–0.91 for different brain regions). Plasma P-tau181 differentiated AD dementia from non-AD neurodegenerative diseases with an accuracy similar to that of Tau PET and CSF P-tau181 (AUC = 0.94–0.98), and detected AD neuropathology in an autopsy-confirmed cohort. High plasma P-tau181 was associated with subsequent development of AD dementia in cognitively unimpaired and MCI subjects. In conclusion, plasma P-tau181 is a noninvasive diagnostic and prognostic biomarker of AD, which may be useful in clinical practice and trials.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Nature Medicine
volume
26
issue
3
pages
8 pages
publisher
Nature Publishing Group
external identifiers
  • pmid:32123385
  • scopus:85081614052
ISSN
1078-8956
DOI
10.1038/s41591-020-0755-1
language
English
LU publication?
yes
id
e7f1c182-c709-4cd2-a5a2-8036408e5696
date added to LUP
2020-04-02 15:56:04
date last changed
2024-11-01 01:58:14
@article{e7f1c182-c709-4cd2-a5a2-8036408e5696,
  abstract     = {{<p>Plasma phosphorylated tau181 (P-tau181) might be increased in Alzheimer’s disease (AD), but its usefulness for differential diagnosis and prognosis is unclear. We studied plasma P-tau181 in three cohorts, with a total of 589 individuals, including cognitively unimpaired participants and patients with mild cognitive impairment (MCI), AD dementia and non-AD neurodegenerative diseases. Plasma P-tau181 was increased in preclinical AD and further increased at the MCI and dementia stages. It correlated with CSF P-tau181 and predicted positive Tau positron emission tomography (PET) scans (area under the curve (AUC) = 0.87–0.91 for different brain regions). Plasma P-tau181 differentiated AD dementia from non-AD neurodegenerative diseases with an accuracy similar to that of Tau PET and CSF P-tau181 (AUC = 0.94–0.98), and detected AD neuropathology in an autopsy-confirmed cohort. High plasma P-tau181 was associated with subsequent development of AD dementia in cognitively unimpaired and MCI subjects. In conclusion, plasma P-tau181 is a noninvasive diagnostic and prognostic biomarker of AD, which may be useful in clinical practice and trials.</p>}},
  author       = {{Janelidze, Shorena and Mattsson, Niklas and Palmqvist, Sebastian and Smith, Ruben and Beach, Thomas G. and Serrano, Geidy E. and Chai, Xiyun and Proctor, Nicholas K. and Eichenlaub, Udo and Zetterberg, Henrik and Blennow, Kaj and Reiman, Eric M. and Stomrud, Erik and Dage, Jeffrey L. and Hansson, Oskar}},
  issn         = {{1078-8956}},
  language     = {{eng}},
  month        = {{03}},
  number       = {{3}},
  pages        = {{379--386}},
  publisher    = {{Nature Publishing Group}},
  series       = {{Nature Medicine}},
  title        = {{Plasma P-tau181 in Alzheimer’s disease : relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia}},
  url          = {{http://dx.doi.org/10.1038/s41591-020-0755-1}},
  doi          = {{10.1038/s41591-020-0755-1}},
  volume       = {{26}},
  year         = {{2020}},
}